Alumis Halts Tepezza Rival, Explores Strategic Alternatives Alumis Inc. halted its unnamed drug program. This drug was a potential Amgen Tepezza rival. Phase 3 development will not proceed. The company is now exploring strategic alternatives. Alumis Inc. has discontinued its unnamed drug program, a late-stage asset targeting Thyroid Eye Disease (TED). The decision follows an internal assessment, leading to the cancellation of planned Phase 3 development. This program aimed to compete with Amgen’s Tepezza, the current market leader. The halt removes a significant potential challenger from the TED therapeutic landscape, impacting future market dynamics. This trial halt signifies a major setback for Alumis. Under FDA regulations, such a decision typically involves notifying the agency of the program's cessation. While no specific 21 CFR reference dictates this halt, sponsors must inform the FDA of significant changes to investigational new drug (IND) applications. This action precludes any future marketing authorization applications (MAA) with the EMA or NDA with the FDA for this specific asset. The discontinuation benefits Amgen, solidifying Tepezza's dominant position in the TED market. Competitors like Viridian Therapeutics (VRDN-001) and Horizon Therapeutics (now Amgen) face one less challenger. This event underscores the high risk in late-stage drug development. Alumis's strategic review is expected to conclude by Q4 2026.